Biotheus, BioNTech Partner on Oncology Bispecific Antibody

Biotheus Inc., a clinical-stage biotech company dedicated to biologics for oncology and inflammatory diseases, has entered into an exclusive global license and collaboration agreement with BioNTech under which BioNTech will develop, manufacture and commercialize PM8002 globally ex-Greater China, where Biotheus retains rights. PM8002 is in Phase 2 studies in China to evaluate the efficacy and safety of the candidate as a monotherapy or in combination with chemotherapy in patients with advanced solid tumors.